ArticleBMC microbiology2025
Antibacterial and photocatalytic potential of piperine-derived zinc oxide nanoparticles against multi-drug-resistant non-typhoidal Salmonella spp.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundDrug-resistant pathogens and industrial dye wastes have emerged as critical global public health concerns, posing significant risks to human and animal health, as well as to environmental sustainability. Green synthesized nano absorbents were found to be a viable strategy for treating drug-resistant pathogens and in wastewater. Hence, this study endeavored the synthesis of piperine-driven nano-zinc oxide (ZnONPs) and evaluated them for antibacterial, antibiofilm, and photocatalytic disinfection potential against multi-drug resistant (MDR) foodborne strains of non-typhoidal Salmonella (NTS). Besides, the dye degradation potential of ZnONPs when exposed to UV, sunlight, and LED lights and their antioxidant capacity were assessed.
resultsInitially, in silico analysis of piperine revealed drug-likeliness with minimal toxicity and strong interaction between piperine and OmpC motifs of Salmonella spp. UV spectroscopy of ZnONPs revealed a prominent absorption peak at 340 nm, while PXRD analysis confirmed the hexagonal wurtzite structure of ZnONPs by exhibiting peaks at 30°, 35.6°, 41.3°, 43.6°, 44.3°, 48°, 53°, 58°, and 59.2°, which corresponded to the lattice planes (102), (110), (103), (200), (112), (004), (104), (210), and (211). Additionally, the TEM images demonstrated predominantly spherical ZnONPs with hexagonal wurtzite crystalline SAED pattern. The minimum inhibitory concentration and minimum bactericidal concentration values (µg/mL) of the ZnONPs were found to be 62.50 and 125, respectively. The ZnONPs were observed to be safe with minimal hemolysis (less than 2%) in chicken RBCs, and no cytopathic effects were observed in the MTT assay using HEK cell lines. The NPs were found to be variably stable (high-end temperatures, proteases, cationic salts, and diverse pH), and were tested safe towards commensal gut lactobacilli. Additionally, in vitro time-kill kinetic assay indicated that the MDR-NTS strains were eliminated after co-incubating with ZnONPs for 6 h. The photocatalytic studies exhibited complete bacterial elimination under visible light at 4 h. Interestingly, the ZnONPs significantly inhibited the biofilm formation in the crystal violet staining assay by MDR-NTS strains (P < 0.001) at 24 and 48 h. Besides, a dose-dependent reducing power assay and 2,2'- azinobis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS
conclusionsThis study revealed a sustainable one-pot method of synthesizing ZnONPs from piperine, which might be used as a viable antibacterial candidate with antioxidant, antibiofilm, and photocatalytic properties with eco-friendly implications and wastewater treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.